Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients

Imagem de Miniatura
Arquivos
art_LIMA_Ability_of_a_Combined_FIB4miRNA181a_Score_to_Predict_2021.PDF (2.83 MB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
ARRESE, Marco
Citação
BIOMEDICINES, v.9, n.12, article ID 1751, 14p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Liver biopsy is the gold standard for assessing fibrosis, but there is a need to seek non-invasive biomarkers for this purpose. The aim of this study was to evaluate the correlation between the serum levels of the microRNAs miR-21, miR-29a, miR-122, miR-155 and miR-181a and the phenotypic expression of NAFLD. A cross-sectional study was carried out on 108 NAFLD patients diagnosed by liver biopsy. FIB-4 and NAFLD fibrosis scores were calculated. The comparison between the distributions of microRNA values according to the presence or absence of histological fibrosis (F2-F4) was performed. A multivariate logistic regression analysis was performed to build a score for predicting fibrosis using FIB-4 and Ln (miR-181a) as independent variables. Only miR-181a showed a statistical difference between patients with significant liver fibrosis (>F2) and those without (F0-F1) (p = 0.017). FIB-4 revealed an AUC on the ROC curve of 0.667 to predict clinically significant fibrosis (F2-F4). When assessed using the score in association with Ln (miR-181a), there was an improvement in the ROC curve, with an AUC of 0.71. miR-181a can be used as a non-invasive method of predicting fibrosis in NAFLD, and an association with FIB-4 has the potential to increase the accuracy of each method alone.
Palavras-chave
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, microRNAs, miR-181a, liver fibrosis, FIB-4
URI
https://observatorio.fm.usp.br/handle/OPI/44440
Referências
  1. Afonso MB, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030030
  2. Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
  3. Benhamouche-Trouillet S, 2016, GUT, V65, P1781, DOI 10.1136/gutjnl-2015-310044
  4. Blaya D, 2018, HEPATOLOGY, V68, P691, DOI 10.1002/hep.29833
  5. Boursier J, 2016, J HEPATOL, V65, P570, DOI 10.1016/j.jhep.2016.04.023
  6. Boyle M, 2019, JHEP REP, V1, P188, DOI 10.1016/j.jhepr.2019.06.004
  7. Cassinotto C, 2016, HEPATOLOGY, V63, P1817, DOI 10.1002/hep.28394
  8. Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367
  9. Ciardullo S, 2021, J HYPERTENS, V39, P1621, DOI 10.1097/HJH.0000000000002835
  10. Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
  11. Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
  12. Cotter TG, 2020, GASTROENTEROLOGY, V158, P1851, DOI 10.1053/j.gastro.2020.01.052
  13. do Amaral AE, 2018, PHARMACOL RES, V134, P179, DOI 10.1016/j.phrs.2018.06.019
  14. Du XL, 2017, ONCOTARGET, V8, P91362, DOI 10.18632/oncotarget.20523
  15. Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368
  16. Eslam M, 2020, GASTROENTEROLOGY, V158, P1999, DOI 10.1053/j.gastro.2019.11.312
  17. Gallego-Duran R, 2015, WORLD J HEPATOL, V7, P2497, DOI 10.4254/wjh.v7.i24.2497
  18. Gennarino VA, 2009, GENOME RES, V19, P481, DOI 10.1101/gr.084129.108
  19. Gori M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/741465
  20. Gupta P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214534
  21. Hagstrom H, 2017, J HEPATOL, V67, P1265, DOI 10.1016/j.jhep.2017.07.027
  22. Jiang WX, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021787
  23. Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
  24. Li HH, 2015, INT J ONCOL, V47, P1379, DOI 10.3892/ijo.2015.3144
  25. Marchesini G, 2016, J HEPATOL, V64, P1388, DOI 10.1016/j.jhep.2015.11.004
  26. MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
  27. Mazo DF, 2019, ANN HEPATOL, V18, P466, DOI 10.1016/j.aohep.2018.10.004
  28. Miyaaki H, 2014, LIVER INT, V34, pE302, DOI 10.1111/liv.12429
  29. Murakami Y, 2017, HEPATOL RES, V47, P60, DOI 10.1111/hepr.12730
  30. Perez-Gutierrez OZ, 2013, ANN HEPATOL, V12, P416, DOI 10.1016/S1665-2681(19)31004-X
  31. Pourhoseini S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116780
  32. Rinella ME, 2016, NAT REV GASTRO HEPAT, V13, P196, DOI 10.1038/nrgastro.2016.3
  33. Roderburg C, 2011, HEPATOLOGY, V53, P209, DOI 10.1002/hep.23922
  34. Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
  35. Shah N, 2013, J CLIN EXP HEPATOL, V3, P231, DOI 10.1016/j.jceh.2013.09.001
  36. Sherif ZA, 2016, DIGEST DIS SCI, V61, P1214, DOI 10.1007/s10620-016-4143-0
  37. Stefano JT, 2021, ANN HEPATOL, V20, DOI 10.1016/j.aohep.2020.08.070
  38. Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178
  39. Sun CZ, 2015, INT J MOL MED, V35, P847, DOI 10.3892/ijmm.2015.2076
  40. Szabo G, 2016, DIGEST DIS SCI, V61, P1314, DOI 10.1007/s10620-015-4002-4
  41. Takeuchi-Yorimoto A, 2016, TOXICOL LETT, V258, P159, DOI 10.1016/j.toxlet.2016.06.012
  42. Tovo CV, 2019, ANN HEPATOL, V18, P445, DOI 10.1016/j.aohep.2018.09.003
  43. Vilar-Gomez E, 2018, J HEPATOL, V68, P305, DOI 10.1016/j.jhep.2017.11.013
  44. Yamada H, 2015, CLIN CHIM ACTA, V446, P267, DOI 10.1016/j.cca.2015.05.002
  45. Yamada H, 2013, CLIN CHIM ACTA, V424, P99, DOI 10.1016/j.cca.2013.05.021
  46. Yang YL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061499
  47. Younes R, 2021, J HEPATOL, V75, P786, DOI 10.1016/j.jhep.2021.05.008
  48. Zambrano-Huailla R, 2020, ANN HEPATOL, V19, P622, DOI 10.1016/j.aohep.2020.08.066

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/07